Lexicon Pharmaceuticals (NASDAQ: LXRX) earned a $10 million milestone payment from Novo Nordisk A/S following a key Phase 1 development achievement for its obesity candidate, LX9851. The payment marks the third such milestone in 2026.

The payment follows the successful patient dosing milestone in the ongoing Phase 1 clinical program for LX9851, a first-in-class oral small molecule inhibitor of ACSL5. Developed by Lexicon and advanced by Novo Nordisk under an exclusive worldwide license signed in 2025, the drug targets obesity and associated metabolic disorders.

Deal Progress and Financials

With this latest payment, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory, and commercial milestone payments available under the collaboration. The company is also entitled to receive tiered royalties on future net sales of LX9851.

Clinical Development Status

Novo Nordisk initiated the Phase 1 development program for LX9851 in March 2026. The trial investigates the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses compared to placebo in adult subjects who are overweight or obese. The program is expected to be completed in the first quarter of 2027.

What the Numbers Show

The rapid progression from licensing agreement to multiple clinical milestones in just over a year highlights efficient execution. However, the $75 million earned represents only 7.5% of the total $1 billion potential value, indicating that the vast majority of financial upside remains contingent on future development, regulatory, and commercial milestones.

About LX9851

LX9851 is a potent and selective oral small molecule inhibitor of Acyl CoA Synthetase 5 (ACSL5). Preclinical in vivo efficacy data presented at Obesity Week 2024 showed that LX9851, when combined with semaglutide, significantly reduced weight, food intake, and fat mass compared to semaglutide alone. The candidate also mitigated weight regain and had positive effects on liver steatosis when introduced after semaglutide discontinuation in preclinical studies.

Lexicon Pharmaceuticals reported a net loss of $31.8 million for the three months ended June 30, 2026, marking a significant shift from net income of $3.3 million in the corresponding period of 2025. The reversal was primarily driven by a sharp decline in revenues, which dropped to $0.7 million from $28.9 million, alongside rising operational costs. This financial performance underscores the company's transition from licensing-driven revenue streams to capital-intensive clinical development phases, impacting near-term profitability while advancing its pipeline toward potential regulatory approvals.

Total operating expenses increased to $27.2 million from $25.1 million in Q2 2025. Research and development expenses rose to $17.4 million from $15.7 million, reflecting higher external research costs associated with the ongoing SONATA-HCM Phase 3 clinical trial. Selling, general, and administrative expenses also climbed to $9.8 million from $9.4 million due to higher professional and consulting costs. The net loss figure includes non-cash stock-based compensation expense of $3.3 million, compared to $3.2 million in the prior year.

Clinical Pipeline Progress

Despite the financial headwinds, Lexicon advanced key milestones in its cardiometabolic portfolio. Enrollment has been completed in SONATA-HCM, a pivotal Phase 3 placebo-controlled study for sotagliflozin in hypertrophic cardiomyopathy (HCM). The study substantially exceeded its target of 500 patients, covering both non-obstructive (nHCM) and obstructive HCM (oHCM) populations. Top-line results are expected in the first quarter of 2027.

In type 1 diabetes, Lexicon is nearing completion of activities for the resubmission of its New Drug Application (NDA) for ZYNQUISTA. The STENO1 study, conducted by the STENO Diabetes Center in Denmark, is approaching the patient exposure and safety data requirements identified by the U.S. Food and Drug Administration (FDA). Lexicon anticipates submitting the NDA in the fourth quarter of 2026. Additionally, licensee Viatris has obtained regulatory approval for sotagliflozin for heart failure in the United Arab Emirates and Bahrain, with applications submitted in several other markets including Saudi Arabia, Canada, Australia, and Mexico.

Financial Position and Liquidity

As of June 30, 2026, Lexicon held $190.6 million in cash and investments, up from $125.2 million in cash, investments, and restricted cash as of December 31, 2025. This increase reflects net proceeds of $96.2 million from the sale of common and preferred stock in February 2026. In May 2026, the company entered into a $100 million loan facility with Hercules Capital. An initial $55 million tranche was funded at closing to repay a previous loan with Oxford Finance. Two additional tranches of $20 million and $25 million remain available subject to specific clinical, regulatory, and financial milestones.

What the Numbers Show

The divergence between revenue collapse and expense growth highlights the structural shift in Lexicon’s business model. With licensing revenue from the Novo Nordisk deal absent in Q2 2026—having contributed $27.6 million in the prior year—the company’s core product sales of INPEFA generated only $0.7 million. This minimal revenue base is insufficient to cover the elevated burn rate driven by late-stage clinical trials. The substantial increase in cash reserves through equity issuance and debt financing is critical, providing the necessary runway to fund the SONATA-HCM trial analysis and ZYNQUISTA NDA submission without immediate reliance on commercial cash flows.